Fzata Inc.
Halethorpe, MD
- UEI
- SLGDVHJS1Y85
- CAGE
- 7HCP9
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1450 S Rolling Rd, Halethorpe, MD 21227, USA
- Website
- fzata.com
- Founded
- 2015
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Unlocked Labs Inc. | Laramie, WY | — |
| Resvita Bio Inc. | Emeryville, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Vitakey Inc. | Washington, DC | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Biotherapeutics, Inc. | Blacksburg, VA | — |
| Qrono, Inc. | Pittsburgh, PA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Fzata Inc. is a for-profit, woman-owned small business registered in the System for Award Management (SAM) since November 2015, with a registration valid through February 2025. The company appears to specialize in developing innovative biotherapeutic solutions, with a particular focus on engineered probiotic technologies targeting complex medical conditions. Their core competency involves creating novel oral immunotherapies that leverage engineered microorganisms to address challenging health issues, particularly in the gastrointestinal and inflammatory disease domains.
The company has secured multiple significant federal grant awards from civilian health research agencies, including the National Institute of Neurological Disorders and Stroke (NINDS), National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Allergy and Infectious Diseases. Their federal grant portfolio demonstrates a consistent research strategy involving developing oral biotherapeutic interventions for conditions such as irritable bowel syndrome, ulcerative colitis, and Clostridioides difficile infection. Specifically, their most recent and substantial award is a $4,219,969 cooperative agreement to develop FZ006, an engineered probiotic yeast (Saccharomyces boulardii) that secretes neutralizing antibodies against tumor necrosis factor-alpha, with the goal of creating a non-addictive therapeutic for chronic visceral pain. These grants consistently involve preclinical research, proof-of-concept testing, manufacturing development, and preparation for potential first-in-human clinical trials, indicating Fzata Inc.'s strategic approach to translational medical research and biotechnology innovation.
Quick answers
Is Fzata Inc. registered in SAM.gov?
Yes. Fzata Inc.'s SAM.gov registration is active through December 31, 2026.
What is Fzata Inc.'s most recent federal award?
Fzata Inc.'s most recent federal grant award is A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome (UG3NS135350), from National Institute of Neurological Disorders and Stroke (NIH), on September 1, 2024.
On GovTribe
See Fzata Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors